Our goal is ensuring that any treatment you choose, including GLP-1 medications, moves you closer to food freedom, not further from it
Head-to-head trials -- Direct comparisons (e.g., SURPASS-2 comparing tirzepatide to semaglutide) are needed for other drug pairs Real-world tolerability -- Trial populations may not reflect typical patients, who often have comorbidities and concomitant medications Conclusion# The GI side effect profile of GLP-1 drugs is not uniform
The patient needs a custom dosage or form that is not commercially available
In vitro studies provide mechanistic support for the anti-fibrotic actions of incretin receptor agonists in the cardiovascular system
10.1038/s42003-020-01165-z Commun
This distinction is critical: the preserved formula allows repeated doses to be drawn from the same multi-dose vial without risk of contamination, provided proper aseptic technique is maintained